CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test
CapsoVision Inc. shares edged higher in late Wednesday morning trading, outpacing a weaker medical-device sector as investors stayed focused on the company’s pending artificial-intelligence product work rather than its still-thin revenue base. The stock was up 5 cents, or about 0.8%, at $6.67 in the latest available trade at 10:45 a.m. EDT, with volume of 14,335 shares. The iShares U.S. Medical Devices ETF fell about 1.4%, while the SPDR S&P 500 ETF was little changed.